Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported Income from Non-Controlling Interests of $23000.0 for Q1 2026, up 675.0% on a YoY basis from $2967.7 in Q1 2025, and down 43.9% quarter-over-quarter from $41000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Income from Non-Controlling Interests (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Income from Non-Controlling Interests for 17 years, with the latest figure at $23000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests rose 675.0% year-over-year to $23000.0; the trailing twelve-month figure through Mar 2026 stood at $193000.0 (up 394.87% YoY), and the FY2025 full-year result was $166000.0, up 514.81% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at $23000.0, down from $41000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $100000.0 in Q2 2025, with the low at -$48000.0 in Q3 2023.
- Historically, Income from Non-Controlling Interests has averaged $8411.8 across 5 years, with a median of -$4000.0 in 2025.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests slumped 433.33% — and 2025, when it jumped 869.23%.
- Lineage Cell Therapeutics' Income from Non-Controlling Interests stood at -$8000.0 in 2022, then soared by 862.5% to $61000.0 in 2023, then sank by 62.3% to $23000.0 in 2024, then soared by 78.26% to $41000.0 in 2025, then tumbled by 43.9% to $23000.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at $23000.0 (Q1 2026), $41000.0 (Q4 2025), and $29000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | 23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 41,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | -13,000.00 |
| Mar 31, 2024 | -16,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Sep 30, 2023 | -48,000.00 |
| Jun 30, 2023 | 26,000.00 |
| Mar 31, 2023 | -32,000.00 |
| Dec 31, 2022 | -8,000.00 |
| Sep 30, 2022 | -47,000.00 |
| Jun 30, 2022 | -19,000.00 |
| Mar 31, 2022 | -6,000.00 |
| Dec 31, 2021 | -200,000.00 |
| Sep 30, 2021 | -11,000.00 |
| Jun 30, 2021 | -8,000.00 |